Simon Anna, Park Heiyoung, Maddipati Ravikanth, Lobito Adrian A, Bulua Ariel C, Jackson Adrianna J, Chae Jae Jin, Ettinger Rachel, de Koning Heleen D, Cruz Anthony C, Kastner Daniel L, Komarow Hirsh, Siegel Richard M
Inflammatory Biology Section, Laboratory of Clinical Investigation and Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9801-6. doi: 10.1073/pnas.0914118107. Epub 2010 May 10.
TNF, acting through p55 tumor necrosis factor receptor 1 (TNFR1), contributes to the pathogenesis of many inflammatory diseases. TNFR-associated periodic syndrome (TRAPS, OMIM 142680) is an autosomal dominant autoinflammatory disorder characterized by prolonged attacks of fevers, peritonitis, and soft tissue inflammation. TRAPS is caused by missense mutations in the extracellular domain of TNFR1 that affect receptor folding and trafficking. These mutations lead to loss of normal function rather than gain of function, and thus the pathogenesis of TRAPS is an enigma. Here we show that mutant TNFR1 accumulates intracellularly in peripheral blood mononuclear cells of TRAPS patients and in multiple cell types from two independent lines of knockin mice harboring TRAPS-associated TNFR1 mutations. Mutant TNFR1 did not function as a surface receptor for TNF but rather enhanced activation of MAPKs and secretion of proinflammatory cytokines upon stimulation with LPS. Enhanced inflammation depended on autocrine TNF secretion and WT TNFR1 in mouse and human myeloid cells but not in fibroblasts. Heterozygous TNFR1-mutant mice were hypersensitive to LPS-induced septic shock, whereas homozygous TNFR1-mutant mice resembled TNFR1-deficient mice and were resistant to septic shock. Thus WT and mutant TNFR1 act in concert from distinct cellular locations to potentiate inflammation in TRAPS. These findings establish a mechanism of pathogenesis in autosomal dominant diseases where full expression of the disease phenotype depends on functional cooperation between WT and mutant proteins and also may explain partial responses of TRAPS patients to TNF blockade.
肿瘤坏死因子(TNF)通过p55肿瘤坏死因子受体1(TNFR1)发挥作用,参与多种炎症性疾病的发病机制。TNFR相关周期性综合征(TRAPS,OMIM 142680)是一种常染色体显性遗传性自身炎症性疾病,其特征为发热、腹膜炎和软组织炎症的长期发作。TRAPS由TNFR1细胞外结构域的错义突变引起,这些突变影响受体折叠和运输。这些突变导致正常功能丧失而非功能获得,因此TRAPS的发病机制仍是一个谜。在此我们表明,突变型TNFR1在TRAPS患者的外周血单核细胞以及来自两个携带TRAPS相关TNFR1突变的独立基因敲入小鼠品系的多种细胞类型中在细胞内积累。突变型TNFR1不作为TNF的表面受体发挥作用,而是在受到脂多糖(LPS)刺激时增强丝裂原活化蛋白激酶(MAPK)的激活和促炎细胞因子的分泌。炎症增强依赖于小鼠和人类髓系细胞中的自分泌TNF分泌和野生型TNFR1,但在成纤维细胞中并非如此。杂合TNFR1突变小鼠对LPS诱导的脓毒性休克高度敏感,而纯合TNFR1突变小鼠类似于TNFR1缺陷小鼠,对脓毒性休克具有抗性。因此,野生型和突变型TNFR1在不同的细胞位置协同作用,增强TRAPS中的炎症反应。这些发现确立了常染色体显性疾病的发病机制,其中疾病表型的完全表达取决于野生型和突变蛋白之间的功能协作,这也可能解释TRAPS患者对TNF阻断治疗的部分反应。